FACT SHEET v1.0 · May 2026
Cancer Series

Metastatic prostate cancer: the essentials

Your prostate cancer has spread beyond the prostate. This is serious. Treatment for this cancer has been rebuilt in the last ten years. For many men today, this is a long disease that is managed in stages over years, with quality of life as part of the plan. For the full story, see the Metastatic Prostate Cancer Patient Guide.

5+ years
Median survival in hormone-sensitive disease on modern combinations. A meaningful number of men live well past that.
2 states
Hormone-sensitive vs castration-resistant. Your treatment options depend on which one you are in.
100%
Germline (inherited) genetic testing is recommended for every man with metastatic prostate cancer, whatever your family history.

Older numbers do not fit you

If you searched survival before reading this, you likely found numbers from before today's drug combinations were standard. Ask your team for current numbers that fit your state and your volume of disease. Group numbers do not predict your own outcome.

Two states: hormone-sensitive or castration-resistant
Hormone-sensitive
mCSPC
Cancer has spread, but it still responds to lowering testosterone. Most men start here. With today's combinations, the response often lasts several years.
Castration-resistant
mCRPC
Cancer keeps growing even with testosterone low. The drug options change, tumor genetics start to drive choices, and the order you take the drugs in starts to matter.

The shift to castration-resistant is part of how this disease moves over time. Your treatment options change the day you cross over.

If hormone-sensitive: high-volume vs low-volume

How much cancer shows on the scans guides how strong the first-line combination should be.

High-volume
Spread to an organ such as the liver or lungs (other organs less often), OR four or more bone spots with at least one outside the spine and pelvis. Triplet treatment often preferred if you are fit for chemo.
Low-volume
Spread to lymph nodes only, or bone spots limited to the spine and pelvis. Doublet treatment is enough for most men. Adding prostate radiation may help in new (de novo) low-volume disease.
First-line treatment: doublets and triplets (mCSPC)

Hormone therapy (ADT)

Androgen deprivation therapy (ADT) lowers testosterone. Injection (leuprolide, goserelin, degarelix) or daily pill (relugolix). Hormone therapy on its own is no longer the standard first plan.

Doublet: ADT + an ARSI

Add one of abiraterone, enzalutamide, apalutamide, or darolutamide. Standard for most men, especially low-volume.

Triplet: ADT + ARSI + docetaxel

Add 6 cycles of chemo. Largest survival benefit in high-volume disease (ARASENS, PEACE-1) if you are fit for chemo.

Prostate radiation

Added to systemic therapy in new low-volume disease (STAMPEDE arm H). Improves survival in that group.

What to watch for on treatment

Protect your bones

Long-term hormone therapy thins bone. Get a DEXA scan at the start. Calcium 1000 to 1200 mg and vitamin D 800 to 1000 IU per day.

Dental check before bone drugs

If you are starting zoledronic acid or denosumab for bone spots, see a dentist first. Finish major dental work before you begin.

Resistance exercise, 2 to 3 times a week

The best-studied fix for hormone-therapy fatigue and muscle loss. A coached program at the start builds a better habit. Aerobic exercise on other days helps too.

Watch heart and metabolic numbers

Long-term hormone therapy raises the risk of high blood pressure, weight gain, higher cholesterol, and new type 2 diabetes. Your primary care doctor should track these.

Mood, sleep, and thinking changes

About 1 in 3 men on long-term hormone therapy have low mood, broken sleep, or trouble with word-finding and focus. Hot flashes affect 50 to 80 of every 100 men. All of it is treatable, so tell your team.

Ask about palliative care early

Palliative care runs alongside cancer treatment, and it is not hospice. It helps with pain, sleep, mood, and family talks. In studies of other cancers, patients seen by a palliative care team within eight weeks of diagnosis had better quality of life.

The two genetic tests

Germline testing uses blood or saliva and looks for inherited gene changes. Somatic testing is done on tumor tissue or a liquid biopsy. Results may open the door to PARP inhibitors (BRCA1, BRCA2, ATM, others) or pembrolizumab (MSI-high). About half of BRCA2 mutations found on tumor testing are also inherited. An inherited gene change has a 50 out of 100 chance of being passed to each child, brother, or sister. A genetic counselor walks the family through it.

Questions to bring to your next visit
  • Am I hormone-sensitive or castration-resistant right now?
  • If hormone-sensitive, is my disease high-volume or low-volume? What does that mean for my treatment?
  • Am I a candidate for triplet therapy? If not, why not?
  • Have I had germline and somatic genetic testing? What did it show?
  • Should my children, siblings, or parents be tested?
  • Has my case been reviewed at a tumor board? Would a second opinion at a high-volume cancer center add value?
  • Are there clinical trials open for me at this stage?
  • Can I have a copy of my pathology and imaging reports?

Go to the ER for

You have new back pain with leg weakness, numbness, or new bowel or bladder changes (this can mean a tumor is pressing on your spinal cord, and it is an emergency). Severe bone pain hits suddenly after a minor injury, which can be a fracture. You run a fever within 14 days of chemo. You get chest pain, severe trouble breathing, or swelling in one leg. Your thinking changes, or you have a seizure or a severe new headache with vomiting. You cannot urinate at all.

Call your team the same day for

Your bone pain is new or much worse. A rash spreads. You get diarrhea, or you see blood in your stool. A new cough or trouble breathing starts. You feel severely tired and dizzy. You get a new headache or a change in your vision. Your blood pressure runs much higher than usual. You have severe mouth dryness or jaw pain on bone drugs.

The full guide

It has the side-effect tables by drug class, the castration-resistant treatment options, bone-health detail, genetics for your family, and a longer list of questions. Ask for the Metastatic Prostate Cancer Patient Guide.